Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
|Articles|April 27, 2018
Controversies in Urologic Cancer
How can you be sure you’ve selected the best approach for your patients with urologic cancer? As our experts debate developments like MRI fusion biopsy for PCa, HIFU for low-risk prostate cancer, and white light cystoscopy, learn how you can integrate these treatments into your practice.
Advertisement
Having trouble viewing?
Once you access the file, position your mouse over the top middle for a toolbar:
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Advertisement
Advertisement
Trending on Urology Times
1
Study assesses real-world outcomes with intranasal vardenafil for ED
2
Three-year data show durable responses with mitomycin intravesical solution
3
Urocross Expander System enters US commercial use for symptomatic BPH
4
FAQs: The AUA 2025 Guideline on Genitourinary Syndrome of Menopause
5